摘要
肿瘤分子靶向药物具有与化疗药物不同的作用机理。目前对肿瘤的疗效评价标准主要是针对化疗药物疗效的评价,从最早的WHO标准发展到RECIST和RECIST 1.1标准,尽管在细节和标准化方面不断完善,但均以测量肿瘤的大小作为评价指标,其原理基于化疗药物直接杀死肿瘤细胞。但是,靶向治疗药物主要是抑制肿瘤细胞增殖,其对肿瘤的作用模式不同于化疗药物,因此近几年出现了对靶向药物疗效评价标准的探索,本文对以CT值作为功能学指标的肿瘤疗效评价标准-Choi标准及其后续的一系列m Choi、SACT、MASS的肿瘤疗效评价标准进行了详述。
The era of targeted molecular therapy for cancer has arrived. The mechanisms of targeted molecular drugs are different from those of chemotherapy drugs. The tumor response evaluation criteria that we currently use are the summary of experiences from evaluating the effect of chemotherapy drugs. Despite continuous improvement and standardization of the details, tumor response evalua-tion criteria, from the earliest WHO criteria to the improved RECIST and RECIST 1.1 criteria, are all based on measurement of tumor size, as chemotherapy drugs directly kill tumor cells. The aforementioned criteria are outlined in this review. However, targeted molecu-lar drugs mainly inhibit tumor cell proliferation. The effect of targeted molecular drugs on tumors is different from that of chemothera-py drugs. Thus, tumor response evaluation criteria suitable for targeted molecular drugs have been developed in recent years. This re-view introduces Choi criteria that use CT attenuation coefficient （Hounsfield unit [HU]） to describe tumor density. The criteria have measured indicators that include tumor size and tumor density. This review also introduces the following criteria derived from the Choi criteria for Modified Choi （mChoi） criteria size and attenuation CT （SACT）, and morphology, attenuation, size, and structure （MASS）.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2015年第6期366-370,共5页
Chinese Journal of Clinical Oncology
关键词
肿瘤疗效评价标准
靶向药物治疗
response evaluation criteria in solid tumors
targeted molecular therapy
